Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015.

Sarrazin C, Buggisch P, Mauss S, Müller T, Zimmermann T, Klinker H, Pathil-Warth A, Schlag M, Nalpas C, Wegner S, Lonjon-Domanec I, Simon KG.

Z Gastroenterol. 2019 May;57(5):584-592. doi: 10.1055/a-0859-7561. Epub 2019 May 13.

PMID:
31083746
2.

Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications.

Marra F, Höner Zu Siederdissen C, Khoo S, Back D, Schlag M, Ouwerkerk-Mahadevan S, Bicer C, Lonjon-Domanec I, Jessner W, Beumont-Mauviel M, Kalmeijer R, Cornberg M.

Br J Clin Pharmacol. 2018 May;84(5):961-971. doi: 10.1111/bcp.13519. Epub 2018 Feb 21.

3.

Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease.

Hézode C, Almasio PL, Bourgeois S, Buggisch P, Brown A, Diago M, Horsmans Y, Serfaty L, Szalay F, Gaeta GB, Planas R, Schlag M, Lonjon-Domanec I, Omoruyi E, DeMasi R, Zeuzem S.

Liver Int. 2017 Sep;37(9):1304-1313. doi: 10.1111/liv.13376. Epub 2017 Mar 13.

PMID:
28135777
4.

Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection.

D'Offizi G, Cammà C, Taibi C, Schlag M, Weber K, Palma M, DeMasi R, Janssen K, Witek J, Lionetti R.

New Microbiol. 2017 Jan;40(1):19-26. Epub 2017 Jan 9.

5.

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response.

Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxí A, Buggisch P, Sanai F, Bicer C, Lenz O, Van Dooren G, Nalpas C, Lonjon-Domanec I, Schlag M, Buti M.

PLoS One. 2017 Jan 5;12(1):e0168713. doi: 10.1371/journal.pone.0168713. eCollection 2017.

6.

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1).

Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxí A, Buggisch P, Ryan R, Lenz O, Scott J, Van Dooren G, Lonjon-Domanec I, Schlag M, Buti M.

PLoS One. 2016 Jul 18;11(7):e0158526. doi: 10.1371/journal.pone.0158526. eCollection 2016.

7.

Reasons for not starting antiretroviral therapy in HIV-1-infected individuals: a changing landscape.

Fehr J, Nicca D, Goffard JC, Haerry D, Schlag M, Papastamopoulos V, Hoepelman A, Skoutelis A, Diazaraque R, Ledergerber B.

Infection. 2016 Aug;44(4):521-9. doi: 10.1007/s15010-016-0887-x. Epub 2016 Mar 16.

PMID:
26983974
8.

Killing of staphylococci by θ-defensins involves membrane impairment and activation of autolytic enzymes.

Wilmes M, Stockem M, Bierbaum G, Schlag M, Götz F, Tran DQ, Schaal JB, Ouellette AJ, Selsted ME, Sahl HG.

Antibiotics (Basel). 2014;3(4):617-31. doi: 10.3390/antibiotics3040617.

9.

Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region.

Sarrazin C, Lathouwers E, Peeters M, Daems B, Buelens A, Witek J, Wyckmans Y, Fevery B, Verbinnen T, Ghys A, Schlag M, Baldini A, De Meyer S, Lenz O.

Antiviral Res. 2015 Apr;116:10-6. doi: 10.1016/j.antiviral.2015.01.003. Epub 2015 Jan 19.

10.

Repeating structures of the major staphylococcal autolysin are essential for the interaction with human thrombospondin 1 and vitronectin.

Kohler TP, Gisch N, Binsker U, Schlag M, Darm K, Völker U, Zähringer U, Hammerschmidt S.

J Biol Chem. 2014 Feb 14;289(7):4070-82. doi: 10.1074/jbc.M113.521229. Epub 2013 Dec 26.

11.

Epidermin and gallidermin: Staphylococcal lantibiotics.

Götz F, Perconti S, Popella P, Werner R, Schlag M.

Int J Med Microbiol. 2014 Jan;304(1):63-71. doi: 10.1016/j.ijmm.2013.08.012. Epub 2013 Sep 4. Review.

PMID:
24119540
12.

Economic burden of late presentation in HIV disease in Austria: a comparison of the initial costs imposed by advanced HIV disease vs. non-late presentation.

Grabmeier-Pfistershammer K, Rieger A, Schröck T, Schlag M.

Wien Klin Wochenschr. 2013 Jul;125(13-14):402-7. doi: 10.1007/s00508-013-0392-5. Epub 2013 Jun 27.

PMID:
23807043
13.

Proton-binding capacity of Staphylococcus aureus wall teichoic acid and its role in controlling autolysin activity.

Biswas R, Martinez RE, Göhring N, Schlag M, Josten M, Xia G, Hegler F, Gekeler C, Gleske AK, Götz F, Sahl HG, Kappler A, Peschel A.

PLoS One. 2012;7(7):e41415. doi: 10.1371/journal.pone.0041415. Epub 2012 Jul 23.

14.

Ligand-binding properties and conformational dynamics of autolysin repeat domains in staphylococcal cell wall recognition.

Zoll S, Schlag M, Shkumatov AV, Rautenberg M, Svergun DI, Götz F, Stehle T.

J Bacteriol. 2012 Aug;194(15):3789-802. doi: 10.1128/JB.00331-12. Epub 2012 May 18.

15.

Staphylococcal major autolysin (Atl) is involved in excretion of cytoplasmic proteins.

Pasztor L, Ziebandt AK, Nega M, Schlag M, Haase S, Franz-Wachtel M, Madlung J, Nordheim A, Heinrichs DE, Götz F.

J Biol Chem. 2010 Nov 19;285(47):36794-803. doi: 10.1074/jbc.M110.167312. Epub 2010 Sep 16.

16.

Structural basis of cell wall cleavage by a staphylococcal autolysin.

Zoll S, Pätzold B, Schlag M, Götz F, Kalbacher H, Stehle T.

PLoS Pathog. 2010 Mar 12;6(3):e1000807. doi: 10.1371/journal.ppat.1000807.

17.

Role of staphylococcal wall teichoic acid in targeting the major autolysin Atl.

Schlag M, Biswas R, Krismer B, Kohler T, Zoll S, Yu W, Schwarz H, Peschel A, Götz F.

Mol Microbiol. 2010 Feb;75(4):864-73. doi: 10.1111/j.1365-2958.2009.07007.x. Epub 2010 Jan 25.

18.

Small-colony variant selection as a survival strategy for Staphylococcus aureus in the presence of Pseudomonas aeruginosa.

Biswas L, Biswas R, Schlag M, Bertram R, Götz F.

Appl Environ Microbiol. 2009 Nov;75(21):6910-2. doi: 10.1128/AEM.01211-09. Epub 2009 Aug 28.

19.

Role of the twin-arginine translocation pathway in Staphylococcus.

Biswas L, Biswas R, Nerz C, Ohlsen K, Schlag M, Schäfer T, Lamkemeyer T, Ziebandt AK, Hantke K, Rosenstein R, Götz F.

J Bacteriol. 2009 Oct;191(19):5921-9. doi: 10.1128/JB.00642-09. Epub 2009 Jul 24.

20.

New Jersey hospitals achieve magnet status.

Schlag MK.

N J Med. 1998 Dec;95(12):41-4. No abstract available.

PMID:
16013136
21.

Education: key to the Magnet culture.

Schlag MK.

J Contin Educ Nurs. 2005 Jan-Feb;36(1):12-3. No abstract available.

PMID:
15715201
22.

Health Professions Scholars Program. An academic health center and public education partnership.

Lattimer P, Schlag MK.

N J Med. 2004 Apr;101(4):31-3. No abstract available.

PMID:
15103788
23.

The effect of ketamine/xylazine anesthesia on sensory and motor evoked potentials in the rat.

Zandieh S, Hopf R, Redl H, Schlag MG.

Spinal Cord. 2003 Jan;41(1):16-22.

PMID:
12494316
24.

Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid(A) receptor antagonistic effect.

Furtmüller R, Schlag MG, Berger M, Hopf R, Huck S, Sieghart W, Redl H.

J Pharmacol Exp Ther. 2002 Apr;301(1):168-73.

PMID:
11907171
25.

Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats.

Schlag MG, Hopf R, Zifko U, Redl H.

Acta Neurochir (Wien). 2002 Jan;144(1):63-9.

PMID:
11807648
26.

Efficient carboplatin single therapy in a mouse model of human testicular nonseminomatous germ cell tumor.

Aharinejad S, Fink M, Abri H, Nedwed S, Schlag MG, Macfelda K, Abraham D, Miksovsky A, Höltl E, Höltl W.

J Urol. 2002 Jan;167(1):368-74.

PMID:
11743358
27.

Serial recording of sensory, corticomotor, and brainstem-derived motor evoked potentials in the rat.

Schlag MG, Hopf R, Redl H.

Somatosens Mot Res. 2001;18(2):106-16.

PMID:
11534774
28.

Role of leukocyte accumulation and oxygen radicals in ischemia-reperfusion-induced injury in skeletal muscle.

Schlag MG, Harris KA, Potter RF.

Am J Physiol Heart Circ Physiol. 2001 Apr;280(4):H1716-21.

29.
30.
31.

Brainstem-evoked muscle potentials: their prognostic value in experimental spinal cord injury in the rat.

Sun T, Schlag MG, Hopf R, Shen Q, Redl H.

Somatosens Mot Res. 2000;17(4):317-24.

PMID:
11125875
32.

The effect of mannitol versus dimethyl thiourea at attenuating ischemia/reperfusion-induced injury to skeletal muscle.

Schlag MG, Clarke S, Carson MW, Harris KA, Potter RF.

J Vasc Surg. 1999 Mar;29(3):511-21.

33.

Achieving magnet status.

Schlag MK, Sengin KK, Shendell-Falik N.

Nurs Adm Q. 1998 Summer;22(4):1-10.

PMID:
9727139
34.

Ischemic tolerance in skeletal muscle: role of nitric oxide.

Pudupakkam S, Harris KA, Jamieson WG, DeRose G, Scott JA, Carson MW, Schlag MG, Kvietys PR, Potter RF.

Am J Physiol. 1998 Jul;275(1):H94-9. doi: 10.1152/ajpheart.1998.275.1.H94.

PMID:
9688900
35.

Health systems: opportunities for nursing practice, education and research.

Schlag MK, Sengin KK.

N J Nurse. 1995 Dec;25(10):11. No abstract available.

PMID:
8700635
36.

Case presentations increase nursing's contribution to the financial integrity of the institution.

Bueno MM, Cavanaugh P, Schlag M.

Aspens Advis Nurse Exec. 1994 Aug;9(11):3-4. No abstract available.

PMID:
8060723

Supplemental Content

Loading ...
Support Center